Survival benefit of combined immunotherapy and chemoradiotherapy in locally advanced unresectable esophageal cancer: an analysis based on the SEER database
BackgroundWhile simultaneous chemoradiotherapy remains the established therapeutic modality for patients afflicted with locally advanced esophageal cancer, the effectiveness of this radical approach falls short of the desired outcome. Numerous investigations have illuminated the prospect of enhancin...
Main Authors: | Liangyun Xie, Zhi Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2024-01-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1334992/full |
Similar Items
-
Impact of chemoradiotherapy on the survival of unresectable locally advanced pancreatic cancer: a retrospective cohort analysis
by: Zi-Meng Wang, et al.
Published: (2023-04-01) -
TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma
by: Hideaki Bando, et al.
Published: (2020-04-01) -
Influence of Chemoradiotherapy Strategies and Factors on the Five-Years Survival of Patients with Esophageal Cancer
by: Seyed Kazem Mirinezhad, et al.
Published: (2014-08-01) -
Induction immunochemotherapy followed by definitive chemoradiotherapy for unresectable locally advanced non‐small cell lung cancer: a multi‐institutional retrospective cohort study
by: Leilei Wu, et al.
Published: (2024-03-01) -
Sex differences in cancer-specific survival for locally advanced esophageal cancer after neoadjuvant chemoradiotherapy: A population-based analysis
by: Jiaqiang Wang, et al.
Published: (2022-07-01)